Deals, Partnering

Cyclogenix enters research collaboration with Wyeth and Queensland’s IMBcom

Posted on 26 February 2009

Cyclogenix has granted Wyeth exclusive rights to Cyclogenix’s novel drug discovery technology platform for use in generating therapeutic peptides, and Wyeth will fund research activities focused on using these technologies. Wyeth has an option to acquire all rights and ownership to these technologies from Cyclogenix at the end of the research collaboration term, which may run for up to five years, or earlier under certain conditions.

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif
cabannerad300x150new4gif
e79banner300x150gif
e78banner300x150animgif